Kunitomo et al., 2020 - Google Patents
The Evolution of Precision Medicine in Cystic FibrosisKunitomo et al., 2020
- Document ID
- 18182068647595406685
- Author
- Kunitomo Y
- Britto C
- Publication year
- Publication venue
- Precision in Pulmonary, Critical Care, and Sleep Medicine: A Clinical and Research Guide
External Links
Snippet
Cystic fibrosis (CF) is the most common fatal genetic disease in the US. Since the sequencing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989, better characterization of CFTR mutations led CF to become the first lung disease …
- 201000003883 cystic fibrosis 0 title abstract description 169
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Quon et al. | New and emerging targeted therapies for cystic fibrosis | |
| Veit et al. | From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations | |
| Amaral | Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients | |
| Strug et al. | Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics | |
| Livraghi et al. | Cystic fibrosis and other respiratory diseases of impaired mucus clearance | |
| US11492670B2 (en) | Compositions and methods for targeting cancer-specific sequence variations | |
| Egan | Genetics of cystic fibrosis | |
| Graeber et al. | The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches | |
| Guggino et al. | Macromolecular interactions and ion transport in cystic fibrosis | |
| Alapati et al. | Gene editing and genetic lung disease. Basic research meets therapeutic application | |
| Galietta | Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors | |
| Cao et al. | Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenoviral vectors | |
| Zhang et al. | Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells | |
| Cao et al. | A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations | |
| Wilschanski | Novel therapeutic approaches for cystic fibrosis | |
| WO2013061091A2 (en) | Cystic fibrosis treatment | |
| Lou et al. | Neonatal‐Tissue‐Derived Extracellular Vesicle Therapy (NEXT): A Potent Strategy for Precision Regenerative Medicine | |
| Kulhankova et al. | Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo | |
| Kanagaki et al. | Hydroxypropyl cyclodextrin improves amiodarone-induced aberrant lipid homeostasis of alveolar cells | |
| Elson et al. | Sorting Nexin 10 as a key regulator of membrane trafficking in bone-resorbing osteoclasts: lessons learned from osteopetrosis | |
| Kunitomo et al. | The Evolution of Precision Medicine in Cystic Fibrosis | |
| Colemeadow et al. | Precise treatment of cystic fibrosis–current treatments and perspectives for using CRISPR | |
| Barry et al. | Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning | |
| Büscher et al. | Disease modifying genes in cystic fibrosis: therapeutic option or one-way road? | |
| Sun et al. | Single-cell RNA sequencing reveals different chondrocyte states in femoral cartilage between osteoarthritis and healthy individuals |